Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is), dipeptidyl peptidase‐4 inhibitors (DPP4Is), and glucagon‐like peptide‐1 receptor agonists have been associated with improved cardiovascular ...

These tables have since been corrected in the article and PDF, and schizophrenia and insomnia have been removed from the list of mental health disorders more likely to occur in glucagon-like peptide-1 ...

Introduction: An estimated 74.6% of Kuwaiti adults are classified as overweight or obese. As a result, Glucagon-like peptide 1 receptor agonists (GLP-1 RA) injections such as, Semaglutide, Liraglutide ...

Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmaceutical interventions have advanced medical treatment for obesity, yet little is known about nutrient intake while using a GLP-1RA ...

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...